The notion that the benefits of SGLT2 inhibitors are mediated by non-glycemic mechanisms at the meeting is supported by a number of observations that CKD and cardiovascular disease risk reductions in clinical trials of these drugs have not been associated with glycemic control or the use of other antidiabetic drugs [82]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.